Twist Bioscience (NASDAQ:TWST) Lifted to Hold at Zacks Investment Research

Twist Bioscience (NASDAQ:TWST) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California. “

Several other equities research analysts have also recently weighed in on the company. Robert W. Baird increased their target price on Twist Bioscience from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, February 5th. They noted that the move was a valuation call. JPMorgan Chase & Co. cut Twist Bioscience from a “neutral” rating to an “underweight” rating and set a $100.00 target price for the company. in a report on Friday, February 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $110.50.

TWST opened at $127.64 on Thursday. The stock has a 50-day moving average price of $131.27 and a 200-day moving average price of $127.75. Twist Bioscience has a 12-month low of $25.72 and a 12-month high of $214.07. The stock has a market capitalization of $6.21 billion, a P/E ratio of -34.04 and a beta of 0.83.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Wednesday, February 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. Twist Bioscience had a negative return on equity of 44.62% and a negative net margin of 155.31%. The firm had revenue of $28.16 million during the quarter, compared to analysts’ expectations of $25.26 million. Research analysts expect that Twist Bioscience will post -3.03 EPS for the current fiscal year.

In other Twist Bioscience news, CEO Emily M. Leproust sold 75,000 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $176.53, for a total value of $13,239,750.00. Following the completion of the sale, the chief executive officer now owns 320,188 shares in the company, valued at approximately $56,522,787.64. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 10,000 shares of the stock in a transaction that occurred on Thursday, January 14th. The stock was sold at an average price of $184.34, for a total value of $1,843,400.00. Following the completion of the sale, the chief executive officer now owns 426,789 shares of the company’s stock, valued at approximately $78,674,284.26. The disclosure for this sale can be found here. In the last quarter, insiders sold 157,027 shares of company stock valued at $26,389,861. Company insiders own 7.00% of the company’s stock.

Several large investors have recently made changes to their positions in the company. DekaBank Deutsche Girozentrale raised its position in shares of Twist Bioscience by 13.2% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 12,000 shares of the company’s stock worth $1,786,000 after acquiring an additional 1,400 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in Twist Bioscience during the 4th quarter valued at approximately $1,774,000. Norges Bank bought a new stake in shares of Twist Bioscience in the 4th quarter worth $3,723,000. Grant Street Asset Management Inc. purchased a new position in shares of Twist Bioscience in the 4th quarter worth $45,000. Finally, Perpetual Investment Management Limited purchased a new position in Twist Bioscience during the fourth quarter valued at $1,619,000. 87.90% of the stock is owned by hedge funds and other institutional investors.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Recommended Story: Quiet Period

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.